Przejdź do zawartości
Merck

MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3.

Virology (2014-07-16)
Gang Xu, Fang Yang, Cui-Ling Ding, Jing Wang, Ping Zhao, Wen Wang, Hao Ren
ABSTRAKT

MiR-221 was reported to be upregulated and play roles in tumorigenesis of hepatitis C virus (HCV) associated hepatocellular carcinoma (HCC). However, the role of miR-221 in HCV infection remains unknown. In this study, it was found that miR-221 was upregulated in serum of HCV chronic hepatitis patients and Huh7.5.1 cells infected with HCVcc. Further studies indicated that miR-221 mimic could accentuate anti-HCV effect of IFN-α in HCVcc model, miR-221 mimic could further repressed 10% HCV RNA expression and 35-42% HCV core or NS5A protein expression in HCVcc infected Huh7.5.1 cells treated with 100IU/mL IFN-α, and miR-221 inhibitor resulted in the reverse effects. Furthermore, two members of suppressor of cytokine signaling (SOCS) family, SOCS1 and SOCS3, which are well established inhibitory factors on IFN/JAK/STAT pathway, were identified as the targets of miR-221 and were involved in the effect of miR-221. In conclusion, miR-221 could accentuate IFN׳s anti-HCV effect by targeting SOCS1 and SOCS3.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
MISSION® esiRNA, targeting mouse Socs1
Sigma-Aldrich
MISSION® esiRNA, targeting human SOCS3
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Socs3